Genelux Corporation (GNLX)
3.88
-0.04 (-1.02%)
At close: Jan 28, 2025, 2:58 PM
undefined% (undefined)
| Bid | 3.83 |
| Market Cap | 134.18M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -4.13 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.94 |
| Volume | 266,613 |
| Avg. Volume (20D) | 176,984 |
| Open | 4.10 |
| Previous Close | 3.92 |
| Day's Range | 3.70 - 4.37 |
| 52-Week Range | 1.60 - 12.12 |
| Beta | undefined |
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment o...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2023
Employees 24
Stock Exchange NASDAQ
Ticker Symbol GNLX
Website https://www.genelux.com
Analyst Forecast
According to 4 analyst ratings, the average rating for GNLX stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 350.45% from the latest price.
Buy 75.00%
Hold 0.00%
Sell 0.00%
2 months ago
-19.73%
Genelux shares are trading lower. HC Wainwright & ...
Unlock content with
Pro Subscription
8 months ago
-43.04%
Genelux shares are trading lower after the company announced the pricing of approximately $27.5 million underwritten offering of common stock and accompanying warrants.
